Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
22 janv. 2025 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
14 janv. 2025 07h30 HE
|
Adaptive Biotechnologies
SEATTLE and FORT MYERS, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of...
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
07 janv. 2025 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
02 janv. 2025 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
07 déc. 2024 18h30 HE
|
Adaptive Biotechnologies
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment...
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
03 déc. 2024 07h30 HE
|
Adaptive Biotechnologies
Adaptive Biotechnologies announces over 65 abstracts featuring clonoSEQ MRD testing at the upcoming 66th ASH Annual Meeting
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
07 nov. 2024 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
07 nov. 2024 07h30 HE
|
Adaptive Biotechnologies
clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate ...
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
09 oct. 2024 16h05 HE
|
Adaptive Biotechnologies
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
29 août 2024 07h30 HE
|
Adaptive Biotechnologies
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...